Get started
Author

David James Britton

Observed names: D.J. Britton, David J Britton, David J. Britton
Observed institutions: Buck Institute for Research on Aging, Queen Mary University of London, University of California, San Francisco, King's College London, Proteome Sciences (United Kingdom), Tenovus Cancer Care, Barts Cancer Institute, Cardiff University
ORCID: 0009-0001-8196-6784
Observed ORCID: 0009-0001-8196-6784
OpenAlex ID: A5104110388
MicroRNAs Cooperatively Inhibit a Network of Tumor Suppressor Genes to Promote Pancreatic Tumor Growth and Progression
2013 · Adam E. Frampton, Leandro Castellano, et al. · Gastroenterology · 171
PDF
Bidirectional cross talk between ERα and EGFR signalling pathways regulates tamoxifen-resistant growth
2005 · D.J. Britton, I.R. Hutcheson, et al. · Breast Cancer Research and Treatment · 142
Targeted Quantitation of Site-Specific Cysteine Oxidation in Endogenous Proteins Using a Differential Alkylation and Multiple Reaction Monitoring Mass Spectrometry Approach
2010 · Jason M. Held, Steven R. Danielson, et al. · Molecular & Cellular Proteomics · 132
PDF
Systematic Mapping of Posttranslational Modifications in Human Estrogen Receptor-α with Emphasis on Novel Phosphorylation Sites
2008 · Christian Atsriku, David J. Britton, et al. · Molecular & Cellular Proteomics · 69
Ligand Binding Promotes CDK-Dependent Phosphorylation of ER-Alpha on Hinge Serine 294 but Inhibits Ligand-Independent Phosphorylation of Serine 305
2012 · Jason M. Held, David J. Britton, et al. · Molecular Cancer Research · 30
A novel serine phosphorylation site detected in the n-terminal domain of estrogen receptor isolated from human breast cancer cells
2008 · David J. Britton, Gary K. Scott, et al. · Journal of the American Society for Mass Spectrometry · 30
Computational Analysis of Cholangiocarcinoma Phosphoproteomes Identifies Patient-Specific Drug Targets
2021 · Shirin Elizabeth Khorsandi, Arran D. Dokal, et al. · Cancer Research · 24
PDF
Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemia
2024 · Weronika E. Borek, Luis Nobre, et al. · EBioMedicine · 7
Rituximab and Obinutuzumab Induce Direct B-Cell Death Via B-Cell Receptor (BCR) Signaling, but Rituximab Elicits Stronger BCR-Derived Pro-Survival Signals Diminishing Apoptosis
2019 · Jennifer Edelmann, Arran Dokal, et al. · Blood · 4
Proteomic Analysis Directs Effective Drug Selection in Relapsed AML By Quantifying Drug Targets
2016 · David J Britton, Edmund Wilkes, et al. · Blood · 2
Should LC-MS/MS proteomics guide targeted drug selection for cancer patients?
2015 · David J. Britton, Pedro R. Cutillas · 1
Abstract 2491: Quantification of biomarker expression, phosphorylation, and mutation in cancer using TMT labeling prior to liquid chromatography-multiple reaction monitoring mass spectrometry
2014 · Yi Chen, David J. Britton, et al. · Cancer Research · 1
Liquid chromatography-multiple reaction monitoring mass spectrometry biomarker quantification for breast cancer patient assessment.
2014 · Yi Chen, David J. Britton, et al. · Journal of Clinical Oncology · 1
Supplementary Figure 6 from Preclinical to Clinical Translation of Pharmacokinetic–Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors
2026 · Adriana Savoca, Diana Zindel, et al.
Supplementary Results from Preclinical to Clinical Translation of Pharmacokinetic–Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors
2026 · Adriana Savoca, Diana Zindel, et al.
Supplementary Table S2 from Preclinical to Clinical Translation of Pharmacokinetic–Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors
2026 · Adriana Savoca, Diana Zindel, et al.
Supplementary Table S4 from Preclinical to Clinical Translation of Pharmacokinetic–Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors
2026 · Adriana Savoca, Diana Zindel, et al.
Supplementary Table S7 from Preclinical to Clinical Translation of Pharmacokinetic–Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors
2026 · Adriana Savoca, Diana Zindel, et al.
Supplementary Table S11 from Preclinical to Clinical Translation of Pharmacokinetic–Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors
2026 · Adriana Savoca, Diana Zindel, et al.
Supplementary Figure 2 from Preclinical to Clinical Translation of Pharmacokinetic–Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors
2026 · Adriana Savoca, Diana Zindel, et al.
Supplementary Table S14 from Preclinical to Clinical Translation of Pharmacokinetic–Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors
2026 · Adriana Savoca, Diana Zindel, et al.
Supplementary Figure 7 from Preclinical to Clinical Translation of Pharmacokinetic–Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors
2026 · Adriana Savoca, Diana Zindel, et al.
Supplementary Figure 10 from Preclinical to Clinical Translation of Pharmacokinetic–Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors
2026 · Adriana Savoca, Diana Zindel, et al.
Supplementary Table S8 from Preclinical to Clinical Translation of Pharmacokinetic–Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors
2026 · Adriana Savoca, Diana Zindel, et al.
Supplementary Figure 1 from Preclinical to Clinical Translation of Pharmacokinetic–Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors
2026 · Adriana Savoca, Diana Zindel, et al.
Works count: 62
Citation count: 614
H-index: 7
I10-index: 7
Year
Topic
Type